Circulating melanoma exosomes as diagnostic and prognosis biomarkers

Clinica Chimica Acta

Volumn 454, Issue , 2016, Pages 28-32

  Alegre, Estibaliz ^a   Zubiri, Leyre ^a   Perez Gracia, Jose Luis ^a   González Cao, María ^b   Soria, Lourdes ^a   Martín Algarra, Salvador ^a   González, Alvaro ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Exosomes; Melanoma; Melanoma inhibitory activity; S100B

Indexed keywords

DOPACHROME TAUTOMERASE; MEMBRANE PROTEIN; PROTEIN MIA; PROTEIN S100B; UNCLASSIFIED DRUG; DOPACHROME ISOMERASE; ISOMERASE; MIA PROTEIN, HUMAN; S100B PROTEIN, HUMAN; SCLEROPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CELL LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; EXOSOME; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; CHEMISTRY; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADULT; BIOMARKERS, TUMOR; CELL LINE, TUMOR; EXOSOMES; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT;

EID: 84952683028     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.12.031     Document Type: Article

References (35)

1. Diaz-Lagares A., Alegre E., Arroyo A., et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011, 32:1155-1161.
2. Alegre E., Sammamed M., Fernandez-Landazuri S., Zubiri L., Gonzalez A. Circulating biomarkers in malignant melanoma. Adv. Clin. Chem. 2015, 69:47-89.
3. Tandler N., Mosch B., Pietzsch J. Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids 2012, 43:2203-2230.
4. Deichmann M., Benner A., Bock M., et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J. Clin. Oncol. 1999, 17:1891-1896.
5. Auge J.M., Molina R., Filella X., et al. S-100β and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res. 2005, 25:1779-1782.
6. Egberts F., Hitschler W.N., Weichenthal M., Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res. 2009, 19:31-35.
7. Wevers K.P., Kruijff S., Speijers M.J., Bastiaannet E., Muller Kobold A.C., Hoekstra H.J. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma. Ann. Surg. Oncol. 2013, 20:2772-2779.
8. Sanmamed M.F., Fernandez-Landazuri S., Rodriguez C., et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin. Chem. 2015, 61:297-304.
9. Gonzalez-Cao M., CMdl C., Molina M.A., et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015, (in press).
10. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
11. Felicetti F., Parolini I., Bottero L., et al. Caveolin-1 tumor-promoting role in human melanoma. Int. J. Cancer 2009, 125:1514-1522.
12. Xiao D., Ohlendorf J., Chen Y., et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS ONE 2012, 7.
13. Valenti R., Huber V., Iero M., Filipazzi P., Parmiani G., Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007, 67:2912-2915.
14. Burke M., Choksawangkarn W., Edwards N., Ostrand-Rosenberg S., Fenselau C. Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J. Proteome Res. 2014, 13:836-843.
15. Chen W.X., Cai Y.Q., Lv M.M., et al. Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour Biol. 2014, 35:9649-9659.
16. Lazar I., Clement E., Ducoux-Petit M., et al. Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. Pigment Cell Melanoma Res. 2015, 28:464-475.
17. Peinado H., Aleckovic M., Lavotshkin S., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
18. Alegre E., Sanmamed M.F., Rodriguez C., Carranza O., Martin-Algarra S., Gonzalez A. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch. Pathol. Lab. Med. 2014, 138:828-832.
19. Dai S., Wei D., Wu Z., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 2008, 16:782-790.
20. Mitchell P.J., Welton J., Staffurth J., et al. Can urinary exosomes act as treatment response markers in prostate cancer?. J. Transl. Med. 2009, 7:4.
21. Peng P., Yan Y., Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol. Rep. 2011, 25:749-762.
22. Alber B., Hein R., Garbe C., Caroli U., Luppa P.B. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. Clin. Chem. Lab. Med. 2005, 43:557-563.
23. Deloulme J.C., Assard N., Mbele G.O., Mangin C., Kuwano R., Baudier J. S100A6 and S100A11 are specific targets of the calcium- and zinc-binding S100B protein in vivo. J. Biol. Chem. 2000, 275:35302-35310.
24. Choi D.S., Lee J.M., Park G.W., et al. Proteomic analysis of microvesicles derived from human colorectal cancer cells. J. Proteome Res. 2007, 6:4646-4655.
25. Ghanem G., Loir B., Morandini R., et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int. J. Cancer 2001, 94:586-590.
26. Schmidt J., Bosserhoff A.K. Processing of MIA protein during melanoma cell migration. Int. J. Cancer 2009, 125:1587-1594.
27. Gyorgy B., Szabo T.G., Pasztoi M., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 2011, 68:2667-2688.
28. Melo S.A., Luecke L.B., Kahlert C., et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015, 523:177-182.
29. Muller-Ladner U., Bosserhoff A.K., Dreher K., et al. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:148-154.
30. Rohlwink U.K., Figaji A.A. Biomarkers of brain injury in cerebral infections. Clin. Chem. 2014, 60:823-834.
31. Sanmamed M.F., Fernandez-Landazuri S., Rodriguez C., et al. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin. Chim. Acta 2014, 429:168-174.
32. Logozzi M., De Milito A., Lugini L., et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 2009, 4.
33. Caradec J., Kharmate G., Hosseini-Beheshti E., Adomat H., Gleave M., Guns E. Reproducibility and efficiency of serum-derived exosome extraction methods. Clin. Biochem. 2014, 47:1286-1292.
34. Peterson M.F., Otoc N., Sethi J.K., Gupta A., Antes T.J. Integrated systems for exosome investigation. Methods 2015.
35. Valenti R., Huber V., Filipazzi P., et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006, 66:9290-9298.